See also: Clinical Trial
NCT00128102 is a randomized, double-blind, placebo-controlled trial of oral suberoylanilide hydroxamic acid (Vorinostat, MK-0683) in patients with advanced malignant pleural mesothelioma previously treated with systemic chemotherapy. Other study name is MK-0683-014, 2005_010.
|This item is relevant to you: Pleural mesothelioma||1||0||
- Can't tell